Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDTP-RECIST guided surgery in locally advanced iCCA after GOLP conversion
NCT07208526Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab, lenvatinib, gemcitabine, oxaliplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhongshan Hospital, Fudan University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
toripalimablenvatinibgemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07208526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07208526.